# Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo

Source: https://onco.cc/trials/nct06771609/  
OnCo record `nct06771609` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.

## Summary

Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. is a phase 2, randomised interventional study registered as NCT06771609 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 150 participants, started 2024-09-10 and due to reach its primary completion in 2028-09-10. Interventions recorded: Adebrelimab + VEX metronomic chemotherapy + radiotherapy; Adebrelimab + VEX metronomic chemotherapy. Conditions listed: Advanced Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "Subjects with metastatic triple-negative breast cancer, with clear clinical data records; specific reference to the "American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06771609
- Phase: 2
- Setting: Evaluate the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy With or Without Radiotherapy in Advanced Triple-negative Breast Cancer: a Prospective, Multicenter, Randomized Controlled Phase II Clinical Trial.
- Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT06771609: https://clinicaltrials.gov/study/NCT06771609

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06771609.json